retatrutide cardiovascular Demand for Unapproved Weight-Loss Drug Surges on Social Media VisualAbstract: Retatrutide reduces body weight

From Obesity to Metabolic Health: Why Retatrutide Is a Game-Changer Abstract Obesity and type 2 diabetes have become global health crises, fueling complications such as cardiovascular disease, fatty liver disease, and metabolic syndrome

Why are compounded GLP-1 medications available now if the branded versions already exist

Phase 3 Ramsbacher N

GLP-1 Medicaid Coverage by State Despite some states offering limited coverage of GLP-1s to treat weight loss as far back as a decade ago, most states that currently provide coverage through taxpayer-funded Medicaid programs or state employee health plans have only opted to do so within the past five years

These medications work by activating GLP-1 receptors in pancreatic beta cells, the brain, and gastrointestinal tract

Results at 36 weeks by dose group: The critical finding: the proportion of lean mass loss to total weight loss was comparable to other obesity medications